News and Events

Amy LeBlanc discusses how dogs are helping cure childhood cancers

Amy LeBlanc, D.V.M., Director of the Center for Cancer Research’s Comparative Oncology Program, was recently featured in an Everyday Health article that discusses the importance of studying the connection between cancer in dogs and cancer in children. Dr. LeBlanc says, “By studying [dogs] in the context of clinical trials, it can advance new concepts and better treatment for humans and, potentially, for dogs as patients themselves.”

Diversity of liver cancer cells can impede tumors’ response to immunotherapy

New research from the NCI’s Center for Cancer Research shows that understanding the impacts of cellular diversity on liver tumors’ microenvironment suggests ways to make immunotherapy effective for more patients.

Steve Rosenberg receives Friends of Cancer Research Cancer Leadership Award

Steve Rosenberg, M.D., Ph.D., Chief of the Surgery Branch, recently received the Friends of Cancer Research Cancer Leadership Award. The award recognizes individuals who have been champions for cancer research and steadfast advocates for patients.

Lawrence Samelson receives Cancer Research Institute Coley Award

Lawrence Samelson, M.D., Chief of the Laboratory of Cellular and Molecular Biology, was named a recipient of the Cancer Research Institute’s 2019 William B. Coley Award for Distinguished Research in Basic and Tumor Immunology. The award recognizes scientists for their seminal discoveries in the fields of basic and tumor immunology.

Marston Linehan discusses kidney cancer breakthroughs with the Federal News Network podcast

Marston Linehan, M.D., Chief of the Urologic Oncology Branch, was recently featured on the Federal News Network podcast. During the episode, Dr. Linehan discussed how kidney cancer is not a single disease but rather a number of different cancers that all happen to occur in the kidney. He also discussed how human genetics research has led to advances in kidney cancer, such as discovering that there are multiple genes that cause 17 types of kidney cancer. He says that while there has been much progress, much work is still left to do.

The New York Times highlights the importance of physician-scientists

The New York Times recently posted an editorial highlighting the importance of physician-scientists in the medical field. The article cited several examples of discoveries made by physician-scientists that have changed the history of medicine, including the development of the HPV vaccine by Doug Lowy, M.D., Chief of the Laboratory of Cellular Oncology (LCO), and John Schiller, Ph.D., Deputy Chief of LCO.

Advanced imaging technology reveals pulsed hormone release regulates gene transcription

Using advanced microscopic imaging technology, CCR investigators have correlated a pulsed pattern of hormone release with bursts of transcription, the process in which the genetic information encoded by DNA is written into RNA. They are the first researchers to observe this process at a gene-specific level.

The Center for Cancer Research celebrates National Postdoc Appreciation Week

This week, we’re celebrating National Postdoc Appreciation Week. Our postdocs come from around the world to train at the Center for Cancer Research, and they are vital members of our cancer research community. Hear from some of our international postdocs on why they came here to train, and learn more about our training programs.

Karlyne Reilly discusses childhood cancer on BioMedCentral

Karlyne M. Reilly, Ph.D., Senior Associate Scientist in the Pediatric Oncology Branch, recently wrote a blog for BioMedCentral. In the blog, Dr. Reilly addresses both the difficulties and the importance of accessing and collecting data from childhood cancer clinical trials and initiatives, such as MyPART, to help improve childhood cancer research in the future.

Tumor composition of melanoma indicates potential responses to immunotherapy

The number of genetic mutations in a tumor is thought to influence how well melanoma may respond to immunotherapy, but new research in mice and supported by preliminary human data reveals that the diversity of mutations within a tumor may be a better indicator of response to therapy.

Breadcrumb